Does parathyroid autofluorescence reduces unintentional parathyroidectomy during total thyroidectomy with central lymph node compartment dissection? - Summary - MDSpire
Advertisement
Does parathyroid autofluorescence reduces unintentional parathyroidectomy during total thyroidectomy with central lymph node compartment dissection?
To evaluate the efficacy of intra-operative autofluorescence imaging in reducing the unintentional excision rate of parathyroid glands during total thyroidectomy with central lymph node compartment dissection.
Approach:
Study Design: A randomized prospective study involving patients with thyroid cancer undergoing total thyroidectomy with therapeutic bilateral central lymph node compartment dissection.
Participants: Patients aged over 18 scheduled for non-emergency total thyroidectomy, excluding those with prior neck surgery, hyperparathyroidism, vitamin D deficiency, or certain medications.
Intervention: Participants were randomly assigned to Group A (no autofluorescence) or Group B (with autofluorescence using FLUOBEAM® LX).
Data Collection: Clinicopathological data were recorded, including the number of parathyroid glands identified and postoperative PTH and calcium levels.
Statistical Analysis: Statistical tests were applied to compare groups, with a significance level set at p < 0.05.
Key Findings:
A higher number of parathyroid glands were identified with autofluorescence compared to naked eye visualization (3.84 ± 0.51 vs. 3.69 ± 0.78, p = 0.03).
The distinction between metastatic lymph nodes and parathyroid glands improved with autofluorescence.
The number of parathyroid glands found in specimens was lower in Group B (17 vs. 8, p = 0.06), but this difference was not statistically significant.
Interpretation:
Limitations:
The study did not report long-term outcomes related to hypoparathyroidism.
The sample size may limit the generalizability of the findings.
Conclusion:
Intra-operative autofluorescence imaging may assist in identifying parathyroid glands during total thyroidectomy.
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.